Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 15/20 | 0.67 |
| ▸ | HDAC8 | Q9BY41 | 8/20 | 0.67 |
| ▸ | HDAC1 | Q13547 | 14/20 | 0.60 |
| ▸ | HDAC2 | Q92769 | 4/20 | 0.60 |
| ▸ | HDAC3 | O15379 | 4/20 | 0.60 |
| ▸ | NCOR2 | Q9Y618 | 2/20 | 0.60 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.60 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.60 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.60 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.60 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.60 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.60 |
| ▸ | PTGES | O14684 | 1/20 | 0.44 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1163479 | 0.85 | HDAC6 (0.54) | HDAC6HDAC8HDAC1HDAC2HDAC3 | |
| Hydrochloric Acid SCHEMBL27432653 | 0.83 | HDAC6 (0.69) | HDAC6HDAC8HDAC1HDAC2HDAC3 | |
| SCHEMBL28431899 | 0.82 | HDAC6 (0.58) | HDAC6HDAC8HDAC1HDAC2HDAC3 | |
| SCHEMBL12472745 | 0.82 | HDAC6 (1.00) | HDAC6HDAC8HDAC1HDAC2HDAC3 | |
| SCHEMBL7313150 | 0.80 | HDAC6 (0.64) | HDAC6HDAC8HDAC1HDAC2HDAC3 | |
| SCHEMBL29603132 | 0.79 | HDAC6 (0.58) | HDAC6HDAC8HDAC1HDAC2HDAC3 | |
| SCHEMBL20486813 | 0.79 | HDAC6 (0.58) | HDAC6HDAC8HDAC1HDAC2HDAC3 | |
| SCHEMBL7314341 | 0.79 | HDAC6 (0.58) | HDAC6HDAC8HDAC1HDAC2HDAC3 | |
| SCHEMBL5175761 | 0.79 | HDAC6 (0.69) | HDAC6HDAC8HDAC1HDAC2HDAC3 | |
| Hydrochloric Acid SCHEMBL7314765 | 0.79 | HDAC1 (0.63) | HDAC6HDAC8HDAC1HDAC2HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12129224-B2 | Process for preparing {6-[(diethylamino)methyl]naphthalen-2-yl}methyl [4-(hydroxycarbamoyl)phenyl]carbamate having high purity | ITALFARMACO SPA (IT) | 2024-10-29 | — | — | US | claimed |
| US-20230364089-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OR PREVENTION OF PATHOLOGICAL CONDITIONS ASSOCIATED WITH EXCESS FIBRIN DEPOSITION AND/OR THROMBUS FORMATION | CERENO SCIENT AB (SE) | 2023-11-16 | — | — | US | claimed |
| US-20230348368-A1 | Process for preparing {6-[(diethylamino)methyl]naphthalen-2-yl}methyl [4-(hydroxycarbamoyl)phenyl]carbamate having high purity | ITALFARMACO SPA (IT) | 2023-11-02 | — | — | US | claimed |
| CN-116947703-A | Method for preparing high-purity {6- [ (diethylamino) methyl ] naphthalen-2-yl } methyl [4- (hydroxycarbamoyl) phenyl ] carbamate | 意大发马克股份公司 | 2023-10-27 | — | — | CN | claimed |
| CN-116947702-A | Method for preparing high-purity {6- [ (diethylamino) methyl ] naphthalen-2-yl } methyl [4- (hydroxycarbamoyl) phenyl ] carbamate | 意大发马克股份公司 | 2023-10-27 | — | — | CN | claimed |
| CN-116947701-A | Method for preparing high-purity {6- [ (diethylamino) methyl ] naphthalen-2-yl } methyl [4- (hydroxycarbamoyl) phenyl ] carbamate | 意大发马克股份公司 | 2023-10-27 | — | — | CN | claimed |
| CN-113614066-B | Method for preparing high-purity {6- [ (diethylamino) methyl ] naphthalen-2-yl } methyl [4- (hydroxycarbamoyl) phenyl ] carbamate | 意大发马克股份公司 | 2023-08-29 | — | — | CN | claimed |
| US-11554123-B2 | Compositions and methods for reactivating latent HIV-1 infections | SAINT JOSEPH'S UNIVERSITY (US) | 2023-01-17 | — | — | US | claimed |
| US-20220249477-A1 | METHODS AND COMPOSITIONS FOR TREATING VIRAL OR VIRALLY-INDUCED CONDITIONS | VIRACTA THERAPEUTICS, INC. (US) | 2022-08-11 | — | — | US | claimed |
| US-20220177421-A1 | Process for preparing {6-[(diethylamino)methyl]naphthalen-2-yl}methyl [4-(hydroxycarbamoyl)phenyl]carbamate having high purity | ITALFARMACO SPA (IT) | 2022-06-09 | — | — | US | claimed |
| CN-113614066-A | Process for preparing high purity {6- [ (diethylamino) methyl ] naphthalen-2-yl } methyl [4- (hydroxycarbamoyl) phenyl ] carbamate | 意大发马克股份公司 | 2021-11-05 | — | — | CN | claimed |
| EP-3891124-A1 | PROCESS FOR PREPARING {6-[(DIETHYLAMINO)METHYL]NAPHTHALEN-2-YL}METHYL [4-(HYDROXYCARBAMOYL)PHENYL]CARBAMATE HAVING HIGH PURITY | Italfarmaco SpA (IT) | 2021-10-13 | — | — | EP | claimed |
| WO-2020178776-A9 | PROCESS FOR PREPARING {6-[(DIETHYLAMINO)METHYL]NAPHTHALEN-2-YL}METHYL [4-(HYDROXYCARBAMOYL)PHENYL]CARBAMATE HAVING HIGH PURITY | ITALFARMACO SPA (IT) | 2021-06-24 | — | — | WO | claimed |
| US-20200016168-A1 | COMPOSITIONS AND METHODS FOR REACTIVATING LATENT HIV-1 INFECTIONS | SAINT JOSEPH'S UNIVERSITY | 2020-01-16 | — | — | US | claimed |
| WO-2018160676-A1 | COMPOSITIONS AND METHODS FOR REACTIVATING LATENT HIV-1 INFECTIONS | UNIVERSITY OF THE SCIENCES (US) | 2018-09-07 | — | — | WO | claimed |
| US-9000031-B2 | Thioxanthone-based autophagy inhibitor therapies to treat cancer | SPECTRUM PHARMACEUTICALS, INC. (US) | 2015-04-07 | — | — | US | claimed |
| US-20110275696-A1 | Thioxanthone-Based Autophagy Inhibitor Therapies to Treat Cancer | SPECTRUM PHARMACEUTICALS, INC. | 2011-11-10 | — | — | US | claimed |
| WO-2011112623-A1 | THIOXANTHONE-BASED AUTOPHAGY INHIBITOR THERAPIES TO TREAT CANCER | SPECTRUM PHARMACEUTICALS, INC. (US) | 2011-09-15 | — | — | WO | claimed |
| US-12129224-B2 | Process for preparing {6-[(diethylamino)methyl]naphthalen-2-yl}methyl [4-(hydroxycarbamoyl)phenyl]carbamate having high purity | ITALFARMACO SPA (IT) | 2024-10-29 | — | — | US | disclosed |
| WO-2011112623-A1 | THIOXANTHONE-BASED AUTOPHAGY INHIBITOR THERAPIES TO TREAT CANCER | SPECTRUM PHARMACEUTICALS, INC. (US) | 2011-09-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230364089-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OR PREVENTION OF PATHOLOGICAL CONDITIONS ASSOCIATED WITH EXCESS FIBRIN DEPOSITION AND/OR THROMBUS FORMATION | HDAC3, HDAC1, HDAC5 | HDAC6 8/4885HDAC8 9/4885HDAC1 2/4885 |
| US-20230348368-A1 | Process for preparing {6-[(diethylamino)methyl]naphthalen-2-yl}methyl [4-(hydroxycarbamoyl)phenyl]carbamate having high purity | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CPS1, CYP8B1 | HDAC6 3807/4885HDAC8 2012/4885HDAC1 3278/4885 |
| US-12129224-B2 | Process for preparing {6-[(diethylamino)methyl]naphthalen-2-yl}methyl [4-(hydroxycarbamoyl)phenyl]carbamate having high purity | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CPS1, CYP8B1 | HDAC6 3807/4885HDAC8 2012/4885HDAC1 3278/4885 |
| US-20220177421-A1 | Process for preparing {6-[(diethylamino)methyl]naphthalen-2-yl}methyl [4-(hydroxycarbamoyl)phenyl]carbamate having high purity | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CPS1, CYP8B1 | HDAC6 3807/4885HDAC8 2012/4885HDAC1 3278/4885 |
| US-20110275696-A1 | Thioxanthone-Based Autophagy Inhibitor Therapies to Treat Cancer | ATG7, BECN1, SQSTM1 | HDAC6 59/4885HDAC8 414/4885HDAC1 464/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.